Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity

Osteoprotegerin (OPG) is a glycoprotein that acts as a decoy receptor for receptor activator of nuclear factor κB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand. The OPG/RANKL/receptor activator of nuclear factor κB axis plays an important regulatory role in the skeletal,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2010-05, Vol.55 (19), p.2049-2061
Main Authors: Venuraju, Shreenidhi M., MBBS, Yerramasu, Ajay, MBBS, Corder, Roger, PhD, MRPharmS, Lahiri, Avijit, MBBS, MSc
Format: Article
Language:English
Subjects:
Animals
atherosclerosis
Cardiology
Cardiovascular
Cardiovascular disease
Coronary Artery Disease - etiology
Coronary Artery Disease - metabolism
Coronary Artery Disease - mortality
Coronary vessels
Cytokines
Heart attacks
Humans
Immune system
Internal Medicine
Mortality
osteoprotegerin
Osteoprotegerin - physiology
Predictive Value of Tests
RANK Ligand - physiology
receptor activator of nuclear factor κB ligand
Receptor Activator of Nuclear Factor-kappa B - physiology
TNF-Related Apoptosis-Inducing Ligand - physiology
tumor necrosis factor–related apoptosis-inducing ligand
vascular calcification
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteoprotegerin (OPG) is a glycoprotein that acts as a decoy receptor for receptor activator of nuclear factor κB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand. The OPG/RANKL/receptor activator of nuclear factor κB axis plays an important regulatory role in the skeletal, immune, and vascular systems. The protective role of OPG, in animal models, against vascular calcification has not been replicated in human trials; moreover, increased OPG levels have been consistently associated with the incidence and prevalence of coronary artery disease. There seems to be some dichotomy in the role of OPG, RANKL, and tumor necrosis factor-related apoptosis-inducing ligand in atherosclerosis and plaque stability. In this review, we integrate the findings from some of the important studies and try to draw conclusions with a view to gaining some insight into the complex interactions of the OPG/RANKL/receptor activator of nuclear factor κB axis and tumor necrosis factor-related apoptosis-inducing ligand in the pathophysiology of atherosclerosis.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2010.03.013